Oral and Swallowing Function in Older Adults
NCT06368830
Recruiting
The purpose of this study is to learn about oral and swallowing function in older adults presenting to the emergency department. The hypothesis is that older adults often have problems with oral and swallowing function and these problems relate to other conditions. Study activities are done during the emergency department visit and include providing saliva samples, completing a bedside water swallow test, completing oral function assessments, completing respiratory function tests, and answering... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/15/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Oropharyngeal Dysphagia
Register for Updates
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972
Recruiting
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of MK-2870 plus paclitaxel versus Ramucirumab plus paclitaxel, for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona +35 locations
Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Register for Updates
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
NCT06510504
Recruiting
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: AFFIRM-1 Study Site, Encino, California +20 locations
Conditions: Social Anxiety Disorder
Register for Updates
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
Register for Updates
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
NCT06630234
Recruiting
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: HonorHealth, Scottsdale, Arizona +5 locations
Conditions: Gastrointestinal Stromal Tumor (GIST)
Register for Updates
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Recruiting
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
04/15/2025
Locations: Alabama Clinical Therapeutics, LLC, Birmingham, Alabama +50 locations
Conditions: Female Contraception
Register for Updates
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
NCT06716580
Recruiting
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/15/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +5 locations
Conditions: Lung Cancer, EGFR Gene Mutation
Register for Updates
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137
Recruiting
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Researchers want to know if giving gocatamig and/or I-DXd can treat SCLC that did not respond or sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103), Hackensack, New Jersey +9 locations
Conditions: Small Cell Lung Cancer
Register for Updates
A Study of Oral YUQ-A1007 in Healthy Volunteers
NCT06835296
Recruiting
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies. This study is first-in-human (FIH) study of YUQ-A1007. The goal of this trial is to evaluate the safety, tolerability, and pharmacokinetics of oral YUQ-A1007.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, Anaheim, California
Conditions: Healthy
Register for Updates
A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
NCT06896695
Recruiting
This clinical trial compares the effect a financial intervention, called Financial Compass, to usual care in identifying and addressing financial hardship in patients with head and neck cancer. Previous research has shown that head and neck cancer patients experiencing financial hardship have decreased overall and cancer specific survival. Using a financial intervention, Financial Compass, may be more effective than usual care in identifying and addressing financial hardship in patients with hea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Head and Neck Carcinoma
Register for Updates
Effect of Flavored, Carbonated Drinks on Salivary Flow, Salivary Composition, and Taste Perceptions
NCT06933290
Recruiting
To determine the effect of flavored, carbonated drinks on salivary flow rate, saliva composition, and taste perceptions compared with control drinks (water, carbonated water, non-carbonated)
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/15/2025
Locations: Gatorade Sports Science Institute, Valhalla, New York
Conditions: Taste Perception, Saliva Production
Register for Updates
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
NCT06940895
Recruiting
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: New York Harbor VA Brooklyn Campus, Brooklyn, New York
Conditions: Acanthosis Nigricans
Register for Updates